Supplementary Tables
# , The control placentas were from patients of cervical incompetency without infection or other possible diseases which would increase the risk of abortion or affecting placentation. The sPE patients involved in the current study did not present complications. # , The control placentas were from patients of cervical incompetency without infection or other possible diseases which would increase the risk of abortion or affecting placentation. The sPE patients involved in the current study did not present complications. 
Supplementary Materials and Methods
Whole mount IF assay: For whole-mount fluorescent IHC, the tissues were fixed using 4% PFA and sequentially incubated with 10% FBS, primary antibody at 4 °C for 2 days, secondary antibody and DAPI. The appropriate concentrations of rabbit and mouse IgGs that were equivalent to the corresponding primary antibodies were applied to negative control sections to control for non-specific staining. Images were captured on a Carl Zeiss LSM 780 confocal laser-scanning microscope.
In situ hybridization: Frozen sections were fixed in 4% PFA. Hybridization was performed at 55 °C in a hybridization buffer containing 200 mM NaCl, 13 mM Tris, 5 mM NaH2PO4, 5 mM Na2HPO4, 5 mM EDTA, 50% formamide, 10% dextran sulfate, 1 mg/ml salmon sperm DNA, 2%
BSA and the DIG-labeled cRNA probes forPLAC8. The sections were washed twice at 55 °C in the post-hybridization buffer (1×SSC, 50% formamide, and 0.1% Tween-20) and twice in buffer I (150 mM NaCl and 100 mM Tris, pH 7.5). The sections were blocked in 2% blocking reagent (Roche Diagnostics, Mannheim, Germany) for 1 hour and incubated with a 1:2,000 dilution of the anti-DIG antibody (Roche) overnight at 4 °C. After four washes in buffer I, the sections were rinsed in buffer III (100 mM NaCl, 50 mM MgCl2, and 100 mM Tris, pH 9.5), and the signals were developed before being counterstained with nuclear fast red. 
